The Dangers of Zantac and Ranitidine-Containing Drugs
If you’re one of the millions of Americans suffering from heartburn, you probably know about Zantac. This popular drug, also known as Ranitidine, has been a go-to treatment for chronic heartburn for decades. However, recent studies indicate a potential link between Zantac use and the development of stomach, bladder, and other cancers. Consequently, the FDA has removed all Ranitidine drugs from the market.
Zantac, a widely used medication that relieved millions of Americans, had its share of issues. Studies have shown that the active ingredient in Zantac, Ranitidine, can break down into a harmful substance called NDMA under high storage temperatures. NDMA is a known carcinogen, and its presence has been associated with various types of cancer, including bladder, stomach, and liver cancers. The evidence raises concerns, making it crucial for those at risk to discontinue the use of this drug immediately.
Understanding the FDA’s Request to Withdraw Zantac from the Market
In a decisive move, the FDA has taken action against the dangers posed by Zantac. The FDA announced in April 2020 the complete withdrawal of all prescription and over-the-counter ranitidine drugs, including Zantac. This withdrawal is due to significant risks, such as potential contamination with NDMA, a known carcinogen. As a result, Zantac products are now completely unavailable in the United States, both with prescriptions and over-the-counter purchases. It is important to acknowledge that some individuals may have already experienced the carcinogenic effects of this drug.
The FDA’s decision was based on the identification of high levels of NDMA in certain ranitidine products. These levels exceeded acceptable limits and posed an increased risk of cancer. Additionally, these products’ impurities could escalate over time and under higher temperatures. This presents challenges in maintaining product quality control.
What is NDMA?
NDMA, a probable human carcinogen classified as a group 2A carcinogen, is formed during industrial processes like rocket fuel and pesticide production. Long-term exposure to high levels of NDMA can lead to cancer, although low-level ingestion is not expected to cause harm. The U.S. Food and Drug Administration sets the acceptable daily level of NDMA at 96 nanograms. However, certain Zantac and Ranitidine-containing drugs have been found to contain significantly higher amounts than the acceptable level.
Seek Justice and Compensation for Negative Zantac Side Effects
If you received a stomach, bladder, esophageal, liver, or pancreatic cancer diagnosis after using Zantac or another Ranitidine-containing drug, you may be eligible to file a lawsuit. These lawsuits aim to secure compensation for medical expenses, lost wages, and pain and suffering experienced by patients.
Zantac, once a popular choice for heartburn relief, has been found to have potential toxicity. The FDA deemed it necessary to withdraw Zantac and all Ranitidine drugs from the market to protect consumers from the risks of harmful contamination. Unfortunately, many individuals have already suffered due to the dangers associated with Zantac use.
Our team of skilled attorneys can provide invaluable assistance in such cases. If you or a loved one has been affected by Zantac use, we are here to offer expert legal representation and aid in your pursuit of justice. Our experienced Zantac Lawsuit attorneys can review your medical records, advise you on legal options, guide you through the process, and represent your interests in court if necessary.
We understand the emotional and financial toll caused by cancer and are committed to helping our clients obtain the compensation they rightfully deserve. Waste no time in taking the first step toward seeking justice. Contact us today at 419-843-6663 or complete our online contact form.
